BACKGROUND: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients. OBSERVATIONS: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months. CONCLUSIONS: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.
BACKGROUND: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients. OBSERVATIONS: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months. CONCLUSIONS: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.
Authors: Kamnesh R Pradhan; Julie A Mund; Heather L Claussen; Yasmin C Gosiengfiao; Vlad C Radulescu; Jennifer J Ballard; Ziyue Liu; Terry A Vik; Jamie Case Journal: J Pediatr Hematol Oncol Date: 2015-08 Impact factor: 1.289
Authors: J Mora; A Castañeda; S Perez-Jaume; A Lopez-Pousa; E Maradiegue; C Valverde; J Martin-Broto; X Garcia Del Muro; O Cruz; J Cruz; J Martinez-Trufero; J Maurel; M A Vaz; E de Alava; C de Torres Journal: Br J Cancer Date: 2017-08-08 Impact factor: 7.640